Safety and Preliminary Efficacy of Personalized Neoantigen-pulsed Dendritic Cell Vaccination in Patients With Solid Tumors: An Interim Analysis
Background/Aim: Immune checkpoint inhibitors have improved outcomes in several malignancies; however, their efficacy remains limited in many solid tumors. Personalized cancer immunotherapy targeting tumor-specific neoantigens represents a promising strategy. We conducted an interim analysis to evaluate the tolerability...